Final 'Squid Game' season lifts Netflix above earnings forecasts
LOS ANGELES (Reuters) -The final season of global phenomenon "Squid Game" helped Netflix top Wall Street earnings targets for the second quarter, the streaming service said on Thursday as it raised revenue guidance for the year.
Netflix posted diluted earnings per share of $7.19 for April through June. That topped the $7.08 consensus estimate of analysts polled by LSEG.
The company raised revenue guidance for 2025 to $44.8 billion to $45.2 billion, citing the weakening of the U.S. dollar plus "healthy member growth and ad sales." Its previous guidance was up to $44.5 billion.
For the just-ended quarter, net income came in at $3.1 billion, edging forecasts of $3.06 billion. Revenue totalled $11.08 billion, above the $11.07 billion analyst projection.
Netflix released the third and final season of dystopian Korean drama "Squid Game" a few days before the second quarter ended in June. The show is the most popular non-English Netflix show in the streaming service's history. Season three racked up 122 million views, Netflix said.
Other releases during the quarter included "Sirens," "The Four Seasons" and a third season of "Ginny & Georgia."
The streaming video pioneer stopped disclosing quarterly subscriber numbers this year, instead urging investors to focus on profit as a measure of its success. It said member growth was ahead of its forecast but occurred late in the quarter, which limited the impact on second-quarter revenue.
Netflix has been building an ad-supported service to increase revenue and reel in price-sensitive viewers. It also has added live events such as WWE wrestling to draw advertisers and viewers.
Looking ahead, Netflix forecast revenue of $11.5 billion and net income of nearly $3 billion. Analysts had projected $11.3 billion and $2.9 billion.
The company also has new seasons of two of its biggest shows coming later this year. "Wednesday" returns in August, and the final episodes of "Stranger Things" will be released in November and December.
Netflix previously said it does not expect advertising to be a primary driver of revenue growth in 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
James Van Der Beek was candid with kids over cancer battle
James Van Der Beek was "as honest as possible" with his children about his cancer diagnosis because he didn't want to "confuse" them. The former Dawson's Creek star - who has Olivia, 14, Joshua, 13, Annabel, 11, Emilia, nine, Gwendolyn, six, and Jeremiah, two, with wife Kimberly - was diagnosed with stage 3 colo-rectal cancer last year and didn't want to hide the news from his broos because "they know" when he's not doing well. Speaking on Today, he said: 'I'm far from an expert, but our approach was just to be as honest as possible, as honest to the degree of their understanding, right? Because they know. "They can sense that Dad's having a tough day. "They know if Dad's in pain. They know, and so by not telling them, I think you're confusing them even more." James has found "a lot of beauty" in his health struggles because of the way his kids have responded. He said: "I have kids making me tea. 'Dad, what do you need?' There's been a lot of beauty that's come out of it, but I would love to save everybody this journey, which is why I'm saying get screened." The 48-year-old actor advised other parents in a similar situation to share the news with their children as they will be surprised by the resilience of youngsters. He said: "When you tell them what you're doing, and you tell them the approach, they can see it and they can feel it, and I think it's also your journey is their journey." At the moment, James is "feeling great" but views battling the disease as a "full-time job". He said: "Today, I'm feeling great, yeah. It's been a journey. There are just so many ups and downs and so many unknowns. Cancer is – I call it a full-time job." James has made a number of changes to his life, including practicing yoga and trying the keto diet and has learned to slow down. He told "[I've been finding] the beauty of just taking things a little bit more slowly and prioritizing rest and really allowing that to be the job," he tells And he is happy he has continued to work, with a role in upcoming TV series Elle. He said: "The greatest thing about work is a cancer doesn't exist between action and cut. "It was fun to drop in and just have a blast because it's such a great cast, a great production, and everybody out there is really talented."
Yahoo
19 minutes ago
- Yahoo
Pitney Bowes Inc (PBI) Q2 2025 Earnings Call Highlights: Strategic Moves and Financial ...
Share Repurchase Authorization: Increased to $400 million. Dividend Increase: $0.01 increase for the third consecutive quarter. Free Cash Flow Guidance: Reiterated for the full year. Revenue Guidance: Reduced by $50 million. EBIT Margin Guidance: Tightened by reducing the high end of the range. EPS Guidance: Increased by $0.10. Adjusted Leverage Ratio: Now below 3x. Warning! GuruFocus has detected 4 Warning Sign with PBI. Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Pitney Bowes Inc (NYSE:PBI) reported significant earnings and cash flow growth on a year-over-year basis. The company nearly exhausted its $150 million share repurchase authorization and increased its dividend for the third consecutive quarter. The Board increased the share repurchase authorization to $400 million, reflecting confidence in the company's financial position. The company has a strong free cash flow and liquidity position, with an adjusted leverage ratio now below 3x. The SaaS business within SendTech showed strong performance, with a 17% year-over-year growth for the quarter. Negative Points Pitney Bowes Inc (NYSE:PBI) reduced its revenue guidance range by $50 million due to customer losses in the Presort business. The company tightened its EBIT margin range by bringing down the high end of the range. The reduction in revenue guidance was attributed to previous management decisions not to offer price concessions to at-risk Presort customers. The Presort business has not yet reversed customer losses, impacting revenue and EBIT guidance. The overall shipping revenue was down 2.5% year-over-year for the quarter due to declines in the non-core part of the business. Q & A Highlights Q: With the new share repurchase authorization, do you intend to continue buybacks in 2025, or will you wait to see how the business performs? A: Kurt Wolf, CEO: We can't comment on future market activities, but our historical share purchases reflect where we see value in the company. Our incentive structure, with options at strike prices of $12, $14, and $16, indicates our valuation perspective. With our leverage ratio below 3.0, we have increased access to restricted payments, providing flexibility for future buybacks. Q: Does the appointment of a new CFO change the timing of the strategic review? A: Kurt Wolf, CEO: The new CFO, Paul Evans, accelerates rather than delays the review. We are conducting a thorough internal review, identifying numerous opportunities for shareholder value creation. The internal review will likely continue through 2025, with a more comprehensive review starting in 2026. Q: How is the shipping subsegment within SendTech performing, and what is the outlook for the rest of the year? A: Kurt Wolf, CEO: The overall shipping revenue was down 2.5% year-over-year due to declines in non-core business. However, core shipping grew by 6%. The SaaS business within shipping grew by 17% year-over-year, and we expect it to continue outpacing core shipping revenue. Q: Are there any structural weaknesses in the Presort business following recent customer losses? A: Kurt Wolf, CEO: The reduction in revenue guidance is largely due to competitive losses in Presort, which were avoidable. We believe Presort and SendTech are strong businesses with high profitability and competitive capabilities. We are working to regain lost customers and capture new ones, leveraging our position as a low-cost provider. Q: How do you view the potential for refinancing bonds, given the current high-yield market conditions? A: Paul Evans, CFO: We are considering refinancing options, balancing our debt's average life and coupon rates. We have the liquidity to pay off the 2027 notes, but we will evaluate the best timing and approach based on market conditions and our strategic needs. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Factbox-Trump tariffs threaten India's export edge; key sectors brace for impact
By Vivek Kumar M and Bharath Rajeswaran (Reuters) -U.S. President Donald Trump on Wednesday slapped 25% tariffs on Indian goods, along with an unspecified penalty tied to energy and defence purchases from Russia — a move that, if enforced, could erode India's export competitiveness and weigh on investor sentiment. India's trade surplus with the U.S. — its largest export market — stood at 1.2% of GDP in 2024. Analysts warn halving that surplus could shave 25–40 basis points off GDP, undermining India's 'safe haven' narrative amid a global slowdown. The relative appeal of Indian markets has also faded, with local equities underperforming peers like Vietnam and Indonesia, which have secured trade pacts with Washington. CLSA said the tariff threat adds to uncertainty in an already expensive market. With negotiations set to resume in mid-August, markets expect the final tariff rate to be lower than 25%. But until clarity emerges, export-linked sectors face significant near-term headwinds. See below for a sector snapshot on who is exposed: PHARMACEUTICALS The U.S. accounts for nearly one-third of India's pharma exports (about $9 billion in FY24). Jefferies estimates a 2–8% EPS hit for Biocon, Sun Pharma and Dr. Reddy's, if generics are included. HSBC warns of an up to 17% downside to FY26 earnings forecasts. TEXTILES Exporters like Welspun Living, Gokaldas Exports, Indo Count and Trident derive 40–70% of sales from the U.S. Higher tariffs could shift market share to Vietnam, which benefits from lower U.S. duties. OIL REFINING A proposed penalty on Russian oil imports could hit Reliance Industries and state-run refiners Bharat Petroleum and Hindustan Petroleum. Companies may face higher costs if forced to diversify crude sourcing. AUTO COMPONENTS Automakers have limited U.S. exposure, but parts makers including Bharat Forge and Sona BLW are Motors' Jaguar Land Rover unit is shielded under U.S.-UK/EU trade arrangements. CAPITAL GOODS & CHEMICALS Cummins India, Thermax and KEI Industries have 5–15% U.S. exposure. Chemical exporters such as Navin Fluorine, PI Industries and SRF may face margin pressure, especially on refrigerant gas exports. SOLAR EQUIPMENT Waaree Energies and Premier Energies count the U.S. as a key market. Nearly 20% of Waaree's FY24 revenue came from the U.S., which also accounts for a major chunk of its 59% overseas current order book. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
